Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 5
Journal homepage
16
Views
24
CrossRef citations to date
0
Altmetric
Anti-Inflammatory, Anti-Allergic, Respiratory & GI Agents

Overview: PAF Receptor Antagonists: Recent Advances

Mark Whittaker British Bio-technology Ltd, Watlington Road, Oxford OX4 5LY, UK
Pages 583-623 | Published online: 02 Mar 2011

Reference to Primary Literature

  • Chang MN PAF and PAF antagonists. Drugs of the Future 1986 11 869.
  • Braquet P, Touqui L, Shen TY, Vargaftig BB Perspectives in platelet-activating factor research. Pharmacol. Rev. 1987 39 97.
  • Hosford D, Mencia-Huerta J-M, Page C, Braquet P Natural antagonists of platelet-activating factor. Phytotherapy Res. 1988 2 1.
  • Cooper K, Parry MJ PAF antagonists. Ann. Reports Med. Chem. 1989 24 81.
  • Page CP, Spina D The therapeutic relevance of PAF antagonists. Agents Actions (Suppl.) 1989 28 313.
  • Venuti MC Platelet activating factor receptors. Comprehensive Medicinal Chemistry Hansch C Sammes PG Taylor JB Pergamon 1990 3 715 A thorough review covering earlier work on PAF agonists and antagonists.
  • Hosford D, Braquet P Antagonists of platelet-activating factor: Chemistry, pharmacology and clinical applications. Progress in Medicinal Chemistry Ellis GP West GB Elsevier 1990 27 325.
  • Prescott SM, Zimmerman GA, McIntyre TM Platelet-activating factor. J. Biol. Chem. 1990 265 17381 A brief review on the synthesis and degradation of PAF.
  • Handley DA Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists. Med. Res. Rev. 1990 10 351.
  • Hwang S-B Specific receptors of platelet-activating factor, receptor heterogeneity, and signal transduction mechanisms. J. Lipid Mediators 1990 2 123 This review presents and discusses comparative receptor binding data for a variety of PAF antagonists.
  • Hosford D, Braquet P The potential role of platelet-activating factor in shock and ischemia. J. Crit. Care 1990 5 115 Review of the effects of PAP antagonists in experimental models of shock and ischaemia.
  • Koltai M, Hosford D, Guinot P, Esanu A, Braquet P Platelet activating factor (PAF): A review of its effects, antagonists and possible future clinical implications (Part I). Drugs 1991 42 9 First part of the most recent detailed review on PAF antagonists.
  • Koltai M, Hosford D, Guinot P, Esanu A, Braquet P Platelet activating factor (PAF): A review of its effects, antagonists and possible future clinical implications (Part II). Drugs 1991 42 174 Second part of the most recent detailed review on PAF antagonists.
  • Koltai M, Hosford D, Esanu A, Braquet P Recent progress in PAF antagonist research. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 3.
  • Honda Z-I, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okada H, Toh H, Ito K, Miyamoto T, Shimeu T Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 1991 349 342 First report of the cloning of a PAF receptor.
  • Ye RD, Prossnitz ER, Zou A, Cochrane CG Characterization of a human cDNA that encodes a functional receptor for platelet activating factor. Biochem. Biophys. Res. Commun. 1991 180 105.
  • Nakamura M, Honda Z-I, Izumi T, Sakanaka C, Mutoh H, Minami M, Bito H, Seyama Y, Matsumoto T, Noma M, Shimizu T Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J. Biol. Chem. 1991 266 20400.
  • Schreiber SL, Porco JA Jr, Hawley RC, Desmaele D The development of a PAF receptor binding model: A progress report. New Methods in Drug Research Makriyannis A JR Prous Science Publishers: S.A. 1989 3 13.
  • Dubost JP, Langlois MH, Audry E, Braquet P, Colleter JC, Croeet F, Dallet PH Structure activities in PAF acether antagonist series using molecular lipophilic potential studies. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 261.
  • Dive G, Godfroid J-J, Lamotte-Brasseur J, Batt J-P, Heymans F, Dupont L, Braquet P PAF-receptor. 1. ‘Cache-oreilles’ effect of selected high-potency platelet-activating factor (PAF) antagonists. J. Lipid Mediators 1989 1 201 First report on the ‘Ear Muffs’ model for the PAF-receptor.
  • Batt J-P, Lamouri A, Tavet F, Heymans F, Dive G, Godfroid J-J New hypothesis on the conformation of the PAF-receptor from studies on the geometry of selected platelet-activating factor-antagonists. J. Lipid Mediators 1991 4 343 Report on the flexible multipolarised cylinder model of the PAF receptor that was derived from the ‘Ear Muffs’ model.
  • Hwang S-B, Lee C-SC, Cheah MJ, Shen TY Specific receptor sites for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on rabbit platelet and guinea pig smooth muscle membranes. Biochemistry 1983 22 4756 Early account of the receptor binding technique that is now widely used for measuring PAF antagonist activity in vitro..
  • Shen TY, Hussaini IM Kadsurenone and other related lignans as antagonists of platelet-activating factor receptor. Methods in Enzymology 1990 187 446.
  • Terashita Z-I, Imura Y, Takatani M, Tsushima S, Nishikawa K CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J. Pharmacol. Exp. Ther. 1987 242 263.
  • Takatani M, Tsushima S Structure activity relationships in CV-3988 and CV-6209 PAF antagonist series. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 97 SAR and pharmacology of these important early PAF antagonists is presented.
  • Bartroli J, Carceller E, Merlos M, Giral M, Garcia-Rafanell J, Forn J Design of potent linear PAF antagonists. J. Med. Chem. 1991 34 3328 A report on the SAR for the Uriach linear quaternary nitrogen PAF antagonists in which the structural features required for good receptor binding are considered.
  • Houlihan WJ, Cheon SH, Handley DA, Larson DA Synthesis and pharmacology of a novel class of long-lasting PAF receptor antagonists. J. Lipid Mediators 1991 3 91.
  • Houlihan WJ Structure activity relation-ships in cyclic analogs of PAF with PAF antagonist properties. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 157 Review of quaternary nitrogen PAF antagonists from Sandoz that incorporate cyclic ether spacer groups.
  • Broquet C, Auclair E, Touvay C, Pignol B, Mencia-Huerta J-M, Braquet P Aminoacylates and aminocarbamates of 2-substituted 4-hydroxymethyl 1,3-dioxolans: Structure activity relationships and biological activity as PAF antagonists. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 119.
  • Bartroli J, Carceller E, Merlos M, Garcia-Rafanell J, Forn J Disubstituted tetrahydrofurans and dioxolanes as PAF antagonists. J. Med. Chem. 1991 34 373.
  • Carceller E, Merlos M, Giral M, Bartroli J, Garcia-Rafanell J, Forn J 4-Substituted 2-alkoxytetrahydrofurans as potent and long-lasting PAF antagonists. J. Med. Chem. 1992 35 676.
  • Merlos M, Gomez LA, Giral M, Vericat ML, Garcia-Rafanell J, Forn J Effects of PAF-antagonists in mouse ear oedema induced by several inflammatory agents. Br. J. Pharmacol. 1991 104 990 Report demonstrating topical anti-inflammatory activity of Uriach PAF antagonists: Comparative data is given for WEB 2086 and CV-6209.
  • Viti G, Nannicini R, Pestellini V A new synthesis of oxazolidin-2-ones from trifluoroacetamides. Tetrahedron Lett. 1992 33 377.
  • Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4-octadecylcarbamoyloxy)piperidino carbonyloxypropyloxy]carbonylaminomethyl pyridinium chloride, in several experimentally induced shock models. Arzneim.-Forsch. Drug Res. 1991 41 II 719 First detailed report on the pharmacology of the Eisai PAF antagonist E-5880. Comparative data is given for CV-3988 and CV-6209.
  • Nakamura N, Miyazaki H, Ohkawa N, Oshima T, Koike H An efficient synthesis of platelet-activating factor (PAF) via 1-O-alkyl-2-O-(3-isoxazolyl)-sn-glycero-3-phoshocholine. A new PAF agonist Utilization of the 3-isoxazolyloxy group as a protected hydroxyl. Tetrahedron Lett. 1990 31 699.
  • Terashita Z-I, Kawamura M, Takatani M, Tsushima S, Imura Y, Nishkawa K Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents. J. Pharmacol. Exp. Ther. 1992 260 748 Report on the pharmacology of TCV-309 giving comparative data for CV-3988, CV-6209 and WEB 2086.
  • Lamotte-Brasseur J, Dive G, Lamouri A, Heymans F, Godfroid J-J PAF-receptor. III. Conformational and electronic properties of PAF-like agonists and antagonists. Biochim. Biophys. Acta. 1991 1085 91.
  • Kates M, Adams GA, Blank ML, Snyder F Chemical synthesis and physiological activity of sulfonium analogues of platelet activating factor. Lipids 1991 26 1095.
  • Kertscher H-P, Ostermann G Phospholipid PAF-antagonists. Pharmazie 1991 46 772.
  • Herrmann DBJ, Opitz H-G, Munder PG Antitumor activity of ilmofosine (BM 41.440) in the lewis-lung carcinoma model. Lipids 1991 26 1431.
  • Grue-Sørensen G, Nielsen Kaergaard C GS 1065–180 and related PAF antagonists: Chemistry and Pharmacology. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 97.
  • Honma Y, Kasukabe T, Hozumi M, Akimoto H, Nomura H Induction of differentiation of human myeloid leukemia HL-60 cells by novel nonphosphorus alkyl ether lipids. Lipids 1991 26 1445.
  • Berdel WE, Munder PG Antineoplastic actions of ether lipids related to platelet-activating factor. Platelet-Activating Factor and Related Lipid Mediators Snyder F Plenum Press 1987, 449.
  • Unger C, Eibl H Hexadecylphosphocholine: Preclinical and the first clinical results of a new antitumor drug. Lipids 1991 26 1412.
  • Guthrie RW, Kaplan GL, Mennona FA, Tilley JW, Kierstead RW, Mullin JG, Le Mahieu RA, Zawoiski S, O'Donnell M, Crowley H, Yaremko B, Welton AF Pentadienyl carboxamide derivatives as antagonists of platelet-activating factor. J. Med. Chem. 1989 32 1820.
  • Guthrie RW, Kaplan GL, Mennona FA, Tilley JW, Kierstead RW, O'donnell M, Crowley H, Yaremko B, Welton AF Propenyl carboxamide derivatives as antagonists of platelet activating factor. J. Med. Chem. 1990 33 2856.
  • Tilley JW, O'Donnell M N-[ω-(Heteroaryl) alkyl]carboxamide derivatives as platelet activating factor antagonists: Structure-activity relationships and biological data. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 229 A thorough review of the Hoffmann-La Roche 3-pyridyl series of PAF antagonists.
  • Heuer HO WEB 2347: Pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs. J. Lipid Mediators 1991 4 39 Detailed report on pharmacology of WEB 2347 that contains comparative data for WEB 2086 and WEB 2170.
  • Weber KH, Heuer H Structure-activity relationships and effects of platelet-activating factor antagonists in the hetrazepine series. Int. Arch. Allergy Appl. Immunol. 1989 88 82.
  • Weber KH, Heuer HO Hetrazepines as antagonists of platelet activating factor. Medicinal Res. Rev. 1989 9 181 A comprehensive review of SAR and early pharmacology of WEB 2086 and WEB 2170.
  • Casals-Stenzel J Thieno-triazolo-1,4-diazepines as antagonists of platelet-activating factor: Present status. Lipids 1991 26 1157.
  • Heuer HO, Keller B, Urich K Action of the racemate and the isomers of the platelet-activating factor antagonist bepafant (WEB 2170) after oral administration to guinea-pigs and rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 1991 343 546.
  • Danneberg P, Böke-Kuhn K, Bechtel WD, Lehr E Pharmacological action of some known and possible metabolites of brotizolam. Arzneim.-Forsch./Drug Res. 1986 36 I 587.
  • Terasawa M, Aratani H, Setoguchi M, Tahara T Pharmacological actions of Y-24180: I. A potent and specific antagonist of platelet-activating factor. Prostaglandins 1990 40 553.
  • Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T Pharmacological actions of Y-24180, a new specific antagonist of platelet-activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors. Prostaglandins 1990 40 571.
  • Miyazawa S, Okano K, Shimomura N, Clark RSJ, Kawahara T, Asano O, Yoshimura H, Miyamoto M, Sakuma Y, Muramoto K, Obaishi H, Harada K, Kajima T, Yamada K, Tsundo H, Katayama S, Abe S, Asakawa N, Souda S, Horie T, Sato T, Machida Y, Katayama K, Yamatsu I Structure-activity studies on triazolothienodiazepine derivatives as platelet-activating factor antagonists. Chem. Pharm. Bull. 1991 39 3215 An interesting account of the SAR for E-6123 and analogues.
  • Tsunoda H, Sakuma Y, Harada K, Muramoto K, Katayama S, Horie T, Shimomura N, Clark R, Miyazawa S, Okano K, Machida Y, Katayama K, Yamatsu I Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Arzneim.-Forsch./Drug Res. 1990 40 II 1201 The first detailed report on the pharmacology of the potent Eisai PAF antagonist E-6123: Comparative data is given for WEB 2086, WEB 2170, WEB 2347 and Y-24180.
  • Sakuma Y, Shirato M, Nagaoka J, Obaishi H, Tsunoda H, Katayama S, Ono H, Katayama K Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Arzneim.-Forsch./Drug Res. 1990 41 II 1255.
  • Sakuma Y, Tsunoda H, Shirato M, Katayama S, Yamatsu I, Katayama K Pharmacological effects of oral E6123, a novel PAF antagonist, on biological changes induced by PAF inhalation in guinea pigs. Prostaglandins 1991 42 463.
  • Sakuma Y, Muramoto K, Harada K, Katayama S, Tsunoda H, Katayama K Inhibitory effects of a novel PAF antagonist E6123 on anaphylactic responses in passively and actively sensitized guinea pigs and passively sensitized mice. Prostaglandins 1991 42 541.
  • Tsunoda H, Sakuma Y, Shirato M, Obaishi H, Harada K, Yamada K, Shimomura N, Machida Y, Yamatsu I, Katayama K Activity of a novel thienodiazepine derivative as a platelet-activating factor antagonist in guinea pig lungs. Arzneim.-Forsch./Drug Res. 1991 41 I 224.
  • Yue T-L, Rabinovici R, Farhat M, Feuerstein G Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo. J. Lipid Mediators 1991 3 13.
  • Braquet P, Laurent JP, Rolland A, Martin C, Pommier J, Hosford D, Esanu A From Ginkgolides to N-substituted piperidinothieno diazepines, a new series of highly potent dual antagonists. Adv. Prost. Tromb. Leuk. Res. 1990 21 929.
  • Braquet P, Esanu A New trends in PAF antagonist research: A new series of potent hetrazepine-derived PAF antagonists. Agents Actions 1991 32 34.
  • Yue T-L, Rabinovici R, Farhat M, Feuerstein G Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins 1990 39 469.
  • Rabinovici R, Yue T-L, Farhat M, Smith EF III, Esser KM, Slivjak M, Feuerstein G Platelet activating factor (PAF) and tumor necrosis factor-α(TNFα) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist. J. Pharmacol. Exp. Ther. 1990 255 256.
  • Lindsberg PJ, Yue TL, Frerichs KU, Hallenbeck JM, Feuerstein G Evidence for platelet-activating factor as a novel mediator in experimental stroke in rabbits. Stroke 1990 21 1452.
  • Rabinovici R, Esser KM, Lysko PG, Yue TL, Griswold DE, Hillegass LM, Bugelski PJ, Hallenbeck JM, Feuerstein G Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ. Res. 1991 69 12 Combined administration to rats of low levels of PAF and endotoxin, which on their own have no effect, results in shock.
  • Karasawa A, Rochester JA, Lefer AM Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock. Meth. Find. Exp. Clin. Pharmacol. 1990 12 231.
  • Dyson MC, Bellan JA, Minkes RK, Beckerman RC, Wegmann MJ, Braquet P, McNamara DB, Kadowtiz PJ Influence of SK&F 95587 and BN 50730 on bronchoconstrictor responses in the cat. J. Pharmacol. Exp. Ther. 1990 255 1320.
  • Gilboe DD, Kintner D, Fitzpatrick JH, Emoto SE, Esanu A, Braquet PG, Bazan NG Recovery of postischemic brain metabolism and function following treatment with a free radical scavenger and platelet-activating factor antagonists. J. Neurochem. 1991 56 311.
  • Castañer J, Koltai M, Spinnewyn B, Duverger D, Pirotzky E, Esanu A, Braquet P BN 50739. Drugs Future 1991 16 413 Review of the synthesis and pharmacology of the dual action PAF antagonist/free radical scavenger BN 50739.
  • Walser A, Flynn T, Mason C, Crowley H, Maresca C, Yaremko B, O'Donnell M Triazolobenzo- and triazolothienodiazepines as potent antagonists of platelet activating factor. J. Med. Chem. 1991 34 1209 Report on the SAR for Ro 24–4736: Comparative data is given for WEB 2086.
  • Walser A, Flynn T, Mason C, Crowley H, Maresca C, O'Donnell M Triazolotriazolothienodiazepines as platelet-activating factor antagonists. Steric limitations for the substituent in position 2. J. Med. Chem. 1991 34 1440.
  • Walser A, Flynn T, Mason C Pentacyclic triazolodiazepines as PAF-antagonists. J. Heterocyclic Chem. 1991 28 1121.
  • Crowley HJ, Yaremko B, Selig WM, Janero DR, Burghardt C, Welton AF, O'Donnell M Pharmacology of a potent platelet-activating factor antagonist: Ro 24–4736. J. Pharmacol. Exp. Ther. 1991 259 78 A report on the evaluation of Ro 24–4736 in a variety of animal models.
  • Torr SR, Haskel EJ, VonVoigtlander PF, Bergmann SR, Abendschein DR Inhibition of cyclic flow variations and reocclusion after thrombolysis in dogs by a novel antagonist of platelet-activating factor. J. Am. Coll. Cardiol. 1991 18 1804.
  • Lavé D Structure-activity relationships in pyrrolo[1,2-c]thiazoles PAF receptor antagonists. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 229 Review of the synthesis and SAR of RP 59227 and analogues.
  • Underwood SL, Lewis SA, Raeburn D RP 59227, a novel PAF receptor antagonist: Effects in guinea pig models of airway hyperreactivity. Eur. J. Pharmacol. 1992 210 97.
  • Soler F, Lavé D, James C, Fabre JL, Floch A, Robaut C, Tarahoui L RP 66682 A potent, selective and water-soluble PAF receptor antagonist in the pyrrolothiazole series. J. Lipid Mediators 1990 2 182.
  • Davidsen SK, Summers JB, Conway RG, Rhein DA, Carter GW Synthesis of bicyclic thiazolidine PAF receptor antagonists. Abstracts of the 203rd ACS National Meeting, April 5–10, 1992 American Chemical Society San Francisco, CA 1992 Abstract No. Medi 161.
  • Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K, Tomioka K Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist. Lipids 1991 26 1179.
  • Yamada T, Tomioka K, Saito M, Horie M, Mase T, Hara H, Nagaoka H Pharmacological properties of YM264, a potent and orally active antagonist of platelet-activating factor. Arch. Int. Pharmacodyn. 1990 308 123.
  • Yamada T, Tomioka K, Horie M, Sakurai Y, Nagaoka H, Mase T Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem. Biophys. Res. Commun. 1991 176 781.
  • Tanabe Y, Kubota Y-N, Sanemitsu Y, Itaya N, Suzukamo G Stereoselective synthesis of anti-PAF active thiazolidin-4-ones via cyclocondensation of alkyl α-mercaptocarboxylates with arylimines. Tetrahedron Lett. 1991 32 383.
  • Tanabe Y, Suzukamo G, Komuro Y, Imanishi N, Morooka S, Enomoto M, Kojima A, Sanemitsu Y, Mizutani M Structure-activity relationship of optically active 2-(3-pyridyl)thiazolidin-4-ones as a PAF antagonist. Tetrahedron Lett. 1991 32 379.
  • Komuro Y, Imanishi N, Uchida M, Morooka S Biological effects of orally active platelet-activating factor receptor antagonist SM-10661. Mol. Pharmacol. 1990 38 378.
  • Uchida M, Imanishi N, Sugasawa T, Morooka S Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 1. Effect on passive anaphylactic bronchoconstriction in guinea pigs. Lipids 1991 26 1301.
  • Sugasawa T, Imanishi N, Morooka S Effect of the selective PAF antagonist SM-10661 on an asthmatic model. 2. Effect on antigen-induced dual asthmatic response and infiltration of leukocytes into airways in actively sensitized concious guinea pigs. Lipids 1991 26 1305.
  • Imanishi N, Komuro Y, Morooka S Effect of a selective PAF antagonist SM-10661 ((±)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one HCI) on experimental disseminated intravascular coagulation (DIC). Lipids 1991 26 1391.
  • Herbert JM, Bernat A, Valette G, Gigo V, Lale A, Laplace MC, Lespy L, Savi P, Maffrand JP, Le Fur G Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J. Pharmacol. Exp. Ther. 1991 259 44 The first report on the potent Sanofi PAF antagonist SR 27417: Comparative data is given for WEB 2086.
  • Herbert JM, Lespy L, Maffrand JP Protective effect of SR 27417, a novel PAF antagonist, on lethal anaphylactic and endotoxin-induced shock in mice. Eur. J. Pharmacol. 1991 205 271.
  • Parry MJ, Alabaster VA, Cheeseman HE, De Souza RN, Keir RF In vitro and in vivo profile of UK-74,505; a novel, highly potent and selective dihydropyridine PAF antagonist. J. Lipid Mediators 1990 2 181.
  • Cooper K, Fray MJ, Richardson K, Steele J UK-74,505, a novel and highly potent dihydropyridine PAF antagonist: Synthesis and structure-activity relationships. J. Lipid Mediators 1990 2 212.
  • Alabaster VA, Keir RF, Parry MJ, De Souza RN UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. Agents Actions Suppl. 1991 34 221 Details of the pharmacology of UK-74,505.
  • Musser JH The design of potent orally active leukotriene D4 antagonists with 5-lipoxygenase inhibitory activity. Trends in Medicinal Chemistry 1988 Elsevier Science Publishers 1989, 599.
  • Hodgkin EE, Miller A, Whittaker M A partial pharmacophore for the platelet activating factor (PAF) receptor. Bioorg. Med. Chem. Lett. 1992 2 In press.
  • Whittaker M, Beauchamp CL, Bowles SA, Cackett K, Christodoulou M, Galloway WA, Longstaff DS, McGuinness GP, Miller A, Timmis DJ, Wood LM BB-823, A PAF receptor antagonist with picomolar activity. Pharmacol. Commun. 1992 In press.
  • Houlihan WJ Structure activity relation-ships in 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline PAF antagonists. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 221 Review of SAR and design of SDZ 64–412.
  • Beams RM, Blackwell GJ, Brockwell MA, Cheesman NJ, Demaine DA, Garland LG, Hodson HF, Hyde RM, Islip PJ, Jackson WP, Parke AJ, Rose VS, Sawyer DA, Smith S, Tilling L, Wates PJ Development of a novel series of aralkylthiazoles as specific and competitive antagonists of platelet activating factor (PAF). J. Lipid Mediators 1990 2 210.
  • Kuroda T, Suzuki F A facile and novel synthesis of 5-phenylimidazo[4,5-c][1,8]naphthyridin-4(5H)-ones. J. Heterocyclic Chem. 1991 28 2029.
  • Bitfu T, Gamble NF, Doebber T, Hwang S-B, Shen T-Y, Snyder J, Springer JP, Stevenson R Conformation and activity of tetrahydrofuran lignans and analogues as specific platelet activating factor antagonists. J. Med. Chem. 1986 29 1917.
  • Iwakami S, Ebizuka Y, Sankawa U Lignans and Sesquiterpenoids as PAF antagonists. Heterocycles 1990 30 795.
  • Shen TY Chemical and biochemical characterization of lignan analogs as novel PAF receptor antagonists. Lipids 1991 26 1154.
  • Chiarino D, Fantucci M Synthesis of 2,5-diisoxazolyltetrahydrofurans. J. Heterocyclic Chem. 1991 28 1705.
  • Tsao PS, Stahl GA, Lefer AM, Salvino J, Pietranico S, Nicolaou KC Platelet-activating factor (PAF) antagonistic actions of two new analogues of tetrahydrofurans. J. Lipid Mediators 1989 1 189.
  • Coran SA, Bambagiotti-Alberti M, Melani F, Giannellini V, Vincieri FF, Mulinacci N, Sala R, Moriggi E Synthetic butanolide and tetrahydrofuran lignans with platelet activating factor antagonist activity. Eur. J. Med. Chem. 1991 26 643.
  • Corey EJ, Chen C-P, Parry MJ Dual binding modes to the receptor for platelet activating factor (PAF) of anti-PAF trans-2,5-diarylfurans. Tetrahedron Lett. 1988 29 2899.
  • Ares JJ, Messier RJ, Kornecki E Synthesis of 3,5-disubstituted 1,2,4-triazoles containing trimethoxyphenyl groups: Potential antagonists of platelet activating factor. J. Heterocyclic Chem. 1991 28 1197.
  • Lamotte-Brasseur J, Heymans F, Dive G, Lamouri A, Batt J-P, Redeuilh C, Hosford D, Braquet P, Godfroid J-J PAF receptor and ‘Cache-oreilles’ effect Simple PAF antagonists. Lipids 1991 26 1167.
  • Takeya T, Takeuchi N, Kasama T, Mayuzumi K, Fukaya H, Tobinaga S Biphenyls, a new class of compound that inhibits platelet-activating factors. Chem. Pharm. Bull. 1990 38 559.
  • Brown DS, Bruno M, Davenport RJ, Ley SV Substitution reactions of 2-benzene-sulphonyl cyclic ethers with carbon nucleophiles. Tetrahedron 1989 45 4293.
  • Larock RC, Gong WH Palladium-catalyzed synthesis of trans-2,5-diaryltetrahydrofurans, potent platelet-activating factor antagonists. J. Org. Chem. 1990 55 407.
  • Corey EJ, Bakshi RK, Shibata S, Chen CP, Singh VK A stable and easily prepared catalyst for the enantioselective reduction of ketones. Applications to multistep syntheses. J. Am. Chem. Soc. 1987 109 7925.
  • Ozawa F, Kubo A, Hayashi T Palladium-catalyzed asymmetric arylation of 2,3-dihydrofuran: 1,8-Bis(dimethylamino)naphthalene as an efficient base. Tetrahedron Lett. 1992 33 1485.
  • Ponpipom MM, Hwang S.-B, Doebber TW, Acton JJ, Alberts AW, Bitfu T, Brooker DR, Bugianesi RL, Chabala JC, Gamble NL, Graham DW, Lam M-H, Wu MS (±)-Trans-2-(3-methoxy-5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF-receptor antagonist. Biochem. Biophys. Res. Commun. 1988 150 1213 Initial report on the synthesis and pharmacology of L-659,989.
  • Hwang S-B, Lam M-H, Alberts AW, Bugianesi RL, Chabala JC, Ponpipom MM Biochemical and pharmacological characterization of L-659,989: An extremely potent, selective and competitive receptor antagonist of platelet-activating factor. J. Pharmacol. Exp. Ther. 1988 246 534.
  • Ponpipom MM, Bugianesi RL, Chabala JC Enantioselective cyclisation of chiral butane-1,4-diols to chiral tetrahydrofurans: Synthesis of chiral trans-2-(3-methoxy-5-memylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659, 989), a potent PAF-receptor antagonist. Tetrahedron Lett. 1988 29 6211.
  • Thomson KL, Chang MN, Bugianesi RL, Ponpipom MM, Arison BH, Hucker HB, Sweeney BM, White SD, Chabala JC Metabolism of the platelet-activating factor antagonist (±)-trans-2-(3′-methoxy-5′-methylsulphonyl-4′propoxyphenyl)-5-(3′,4′,5′-trimethoxyphenyl)tetrahydrofuran (L-659,989) in rhesus monkeys. Xenobiotica 1991 21 613.
  • Sahoo SP, Graham DW, Acton J, Biftu T, Bugianesi RL, Girotra NN, Kuo CH, Ponpipom MM, Doebber TW, Wu MS, Hwang S-B, Lam M-H, MacIntyre DE, Bach TJ, Luell S, Meurer R, Davies P, Alberts AW, Chabala JC Synthesis and biological activity of MK 287 (L-680,573): A potent, specific and orally active PAF receptor antagonist. Bioorg. Med. Chem. Lett. 1991 1 327 An initial report on the synthesis and pharmacology of Merck development PAF antagonist MK 287.
  • Simpson P, Tschaen D, Verhoeven TR A practical, one-pot preparation of diisopinocampheylchloroborane. Synth. Commun. 1991 21 449.
  • Thompson AS, Tschaen DM, Simpson P, McSwine D, Russ W, Little ED, Verhoeven TR, Shinkai I Conversion of a silylated hemiacetal into an α-bromoether using trimethylsilybromide. Synthesis of platelet activating factor antagonist L-659,989. Tetrahedron Lett. 1990 31 6953.
  • Bugianesi RL, Ponpipom MM, Parsons WH, Hwang S-B, Doebber TW, Lam M-H, Wu MS, Alberts AW, Chabala JC Synthesis and biological activity of the platelet-activating factor antagonist (±)-trans-2-(3-methoxy-4-phenylsulfonylethoxy-5-n-propylsulfonylphenyl)-5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-671,284) and its analogs. Bioorg. Med. Chem. Lett. 1992 2 181 A report on the SAR for L-671,284, an analogue of L-659,989, which does not exhibit gender dependent oral activity.
  • Prashad M, Tomesch JC, Wareing JR, Smith HC, Cheon SH Palladium catalysed double Heck arylation of cyclopentene. Tetrahedron Lett. 1989 30 2877.
  • Prashad M, Tomesch JC, Shapiro MJ Lewis acid catalyzed stereoselective ene addition of formaldehyde to 1,3-diarylcyclopentenes - Synthesis of trans-2,5-diaryl-2-cyclopentene-1-methanols. Tetrahedron Lett. 1989 30 4757.
  • Stensland B, Batt J-P, Lamouri A, Godfroid J-J Platelet activating factor antagonists. Structure of N,N′-Bis(3,4,5-trimethoxybenzoyl)-2-piperazinylmethyl 2,2-dimethylproponate. Acta. Cryst. 1991 C47 1453.
  • Gottlieb OR, Yoshida M, Romoff P Kadsurenone type neolignans, potential PAF antagonists: Chemistry and distribution. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 81.
  • Braquet P, Esanu A, Buisine E, Hosford D, Broquet C, Koltai M Recent progess in Ginkgolide research. Med. Res. Rev. 1991 11 295 Up to date review on ginkgolide chemistry and pharmacology.
  • Braquet P, Hosford D Ethnopharmacology and the development of natural PAF antagonists as therapeutic agents. J. Ethnopharmacol. 1991 32 135.
  • Korth R, Nunez D, Bidault J, Benveniste J Comparison of three PAF-acether receptor antagonist ginkgolides. Eur. J. Pharmacol. 1988 152 101.
  • Corey EJ, Kang M-C, Desai MC, Ghosh AK, Houpis IN Total synthesis of (±)-ginkgolide B. J. Am. Chem. Soc. 1988 110 649 First report on the toyal synthesis of a ginkgolide.
  • Corey EJ, Gavai AV Enantioselective route to a key intermediate in the total synthesis of ginkgolide B. Tetrahedron Lett. 1988 29 3201.
  • Corey EJ, Ghosh AK Total synthesis of ginkgolide A. Tetrahedron Lett. 1988 29 3205.
  • Villhauer EB, Anderson RC Synthesis of the CDE ring system of the ginkgolides. J. Org. Chem. 1987 52 1186.
  • Trost BM, Acemoglu M A cycloaddition strategy directed toward the spiro ring system of the ginkgolides. Tetrahedron Lett. 1989 30 1495.
  • Crimmins MT, Thomas JB Intramolecular enone-furan photocycloadditions: Studies toward the synthesis of ginkgolides A and B. Tetrahedron Lett. 1989 30 5997.
  • DeLuca MR, Magnus P Studies on the synthesis of ginkgolides. Rapid construction of the spiro[4,4]nonane A and B rings. J. Chem. Soc., Perkin Trans. I 1991, 2661.
  • Corey EJ, Gavai AV Simple analogs of ginkgolide B which are highly active antagonists of platelet activating factor. Tetrahedron Lett. 1989 30 6959 Investigation of SAR for the ginkgolide PAF antagonists.
  • Corey EJ, Rao KS Enantioselective total synthesis of ginkgolide derivatives lacking the tert-butyl group, an essential structural subunit for antagonism of platelet activating factor. Tetrahedron Lett. 1991 32 4623 Investigation of SAR for the ginkgolide PAF antagonists.
  • Schreiber SL, Desmaele D, Porco JA Jr On the use of unsymmetrically substituted furans in the furan-carbonyl photocycloaddition reaction: Synthesis of a kadsurenone-ginkgolide hybrid. Tetrahedron Lett. 1988 29 6689.
  • Sugano M, Shindo T, Sato A, Iijima Y, Oshima T, Kuwano H, Hata T Chatancin, a PAF antagonist from a soft coral. Sarcophyton sp. J. Org. Chem. 1990 55 5803.
  • Sugano M, Sato A, Iijma Y, Oshima T, Furuya K, Kuwano H, Hata T, Hanzawa H Phomactin A: A novel PAF antagonist from a marine fungus Phoma sp. J. Am. Chem. Soc. 1991 113 5463.
  • Kadota S, Marpaung L, Kikuchi T, Ekimoto H Antagonists of Platelet activating factor from Swietenia mahogani (L.) Jacq. Tetrahedron Lett. 1989 30 1111.
  • Ekimoto H, Irie Y, Araki Y, Han G-Q, Kadota S, Kikuchi T Platelet aggregation inhibitors from the seeds of swietenia mahogoni: Inhibition of in vitro and in vivo platelet-activating factor-induced effects of tetranortriterpenoids related to swietenine and swietenolide. Planta Med. 1991 57 56.
  • Lee C-M, Jiang L-M, Shang H-S, Hon P-M, He Y, Wong HNC Prehispanolone, a novel platelet activating factor receptor antagonist from Leonurus heterophyllus. Br. J. Pharmacol. 1991 108 1719.
  • Shen TY, Hussaini, Hwang S-B, Chang MN Recent development of platelet-activating factor antagonists. Adv. Prostaglandin Thromboxane Leukotriene Res. 1989 19 359.
  • Ng DS, Wong K Effect of sulfhydryl reagents on PAF binding to human neutrophils and platelets. Eur. J. Pharmacol. 1988 154 47.
  • Burstein SH, Audette CA, Doyle SA, Hull K, Hunter SA, Latham V Antagonism to the actions of platelet activating factor by a nonpsychoactive cannabinoid. J. Pharmacol Exp. Ther. 1989 251 531.
  • Guinn DE, Summers JB, Heyman HR, Conway RG, Rhein DA, Albert DH, Magoc T, Carter GW Synthesis and structure-activity-relationships of a series of novel benzopyran containing platelet activating factor antagonists. Abstracts of the 203rd ACS National Meeting, April 5–10, 1992 American Chemical Society San Francisco, CA 1992 Abstract No. Medi 162.
  • Hemmi K, Shimazaki N, Shima I, Okamoto M, Yoshida K, Hashimoto M PAF antagonists from microbial origin: Structure-activity relationships of diketopiperazine derivatives. CRC Handbook of PAF and PAF antagonists CRC Press 1991, 71.
  • Shimazaki N, Shima I, Okamoto M, Yoshida K, Hemmi K, Hashimoto M PAF inhibitory activity of diketopiperazines: Structure-activity relationships. Lipids 1991 26 1175 A review of the SAR for FR76600 and analogues.
  • Shima I, Shimazaki N, Imai K, Hemmi K, Hashimoto M Synthesis of optically active β-methyltryptophans from aziridine-2-carboxylates. Chem. Pharm. Bull. 1990 38 564.
  • Sunkel CE, de Casajuana Fau M, Santos L, Gomez MM, Villarroya M, Gonzalez-Morales MA, Priego JG, Ortega MP 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists. J. Med. Chem. 1990 33 3205.
  • Ortega MP, Garcia MDC, Gijon MA, de Casajuana Fau M, Priego JG, Crespo MS, Sunkel CE 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: In vitro pharmacologic studies. J. Pharmacol. Exp. Ther. 1990 255 28.
  • Fernandez-Gallardo S, Ortega MP, Priego JG, de Casajuana Fau M, Sunkel CE, Crespo MS Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: In vivo studies. J. Pharmacol. Exp. Ther. 1990 255 34.
  • Billah MM, Egan RW, Ganguly AK, Green MJ, Kreutner W, Piwinski JJ, Siegel MI, Villani FJ, Wong JK Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine. Lipids 1991 26 1172.
  • Piwinski JJ, Wong JK, Green MJ, Ganguly AK, Billah MM, West RE Jr, Kreutner W Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-acyl-4-(5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines. J. Med. Chem. 1991 34 457 Report on the SAR for Sch 37370 and its analogues.
  • Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W Sch 37370: A potent, orally active, dual antagonist of platelet-activating factor and histamine. J. Pharmacol. Exp. Ther. 1990 255 1090.
  • Billah MM, Chapman RW, Watnick AS, Egan RW, Siegel MI, Kreutner W Sch 37370: A new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991 34 313.
  • Rogers JE, Duronio V, Wong SI, McNeil M, Salari H Solubilization of a functionally active platelet-activating factor receptor from rabbit platelets. Biochem. J. 1991 278 405.
  • Wang C-J, Tai H-H Monoclonal anti-idiotypic antibodies to platelet activating factor (PAF) and their interaction with PAF receptors. J. Biol. Chem. 1990 266 12372.
  • Dent G, Ukena D, Vhanez P, Sybrecht G, Barnes P Characterization of PAF receptors on human neutrophils using the specific antagonist, WEB 2086. FEBS Lett. 1989 244 365.
  • Ukena D, Krogel C, Dent G, Yukawa T, Sybrecht G, Barnes PJ PAF-receptors on eosinophils: Identification with a novel ligand, [3H]WEB 2086. Biochem. Pharmacol. 1989 38 1702.
  • Hwang S-B, Wang S Receptor heterogeneity and the existence of intracellular receptors of platelet-activating factor. Adv. Appl. Biotech. Ser. 1990 9 13.
  • Hwang S-B Function and regulation of extracellular and intracellular receptors of platelet activating factor. Ann. N. Y. Acad. Sci. 1991 629 217 Evidence is presented for an intracellular PAF receptor.
  • Arnout J, Van Hecken A, De Lepeleire I, Miyamoto Y, Holmes I, De Schepper P, Vermylen J Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br. J. Clin. Pharmac. 1988 25 445.
  • Pinquier JL, Sedivy P, Bruno R, Bompart F, Gregoire J, Strauch G, Gaillot J, Clucas A Inhibition of ex-vivo PAF-induced platelet aggregation by the PAF-antagonist RP 48740: Relationships to plasma concentrations in healthy volunteers. Eur. J. Clin. Pharmacol. 1991 41 141.
  • Adamus WS, Heuer H, Meade CJ, Frey G, Brecht HM Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex vivo platelet aggregation. Eur. J. Clin. Pharmacol. 1988 35 237.
  • Adamus WS, Heuer H, Meade CJ PAF-induced platelet aggregation ex vivo as a method for monitoring pharmacological activity in healthy volunteers. Meth. Find. Exp. Clin. Pharmacol. 1989 11 415.
  • Adamus WS, Heuer H, Meade CJ, Brecht HM Safety, tolerability, and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects. Clin. Pharmacol. Ther. 1989 45 270.
  • Brecht HM, Adamus WS, Heuer HO, Birke FW, Kempe ER Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist Apafant in man. Arzneim. Forsch. Drug Res. 1991 41 I 51.
  • Chung KF, Dent G, McCusker M, Guinot P, Page CP, Barnes PJ Effect of a ginkgolide mixture (BN52063) in antagonising skin and platelet responses to platelet-activating factor in man. Lancet 1987 1 248.
  • Hayes JP, Ridge SM, Griffith S, Barnes PJ, Chung KF Inhibition of cutaneous and platelet responses to platelet-activating factor by oral WEB 2086. J. Allergy Clin. Immunol. 1991 88 83.
  • Roberts NM, Page CP, Chung KF, Barnes PJ Effect of a PAF antagonist, BN 52063, on antigen-induced, acute, and late-onset cutaneous responses in atopic subjects. J. Allergy Clin. Immunol. 1988 82 236.
  • Hosford D, Mencia-Huerta JM, Braquet P Platelet-activating factor (PAF) and PAF antagonists in asthma. Crit. Rev. Ther. Drug. Carr. Syst. 1990 7 261.
  • Smith LJ The role of platelet-activating factor in asthma. Am. Rev. Respir. Dis. 1991 143 S100.
  • Editorial PAF antagonists and asthma - time for a rethink?. Pharmaceut. J. 1991, 156.
  • Barnes PJ Platelet activating factor and asthma. Ann. N. Y. Acad. Sci. 1991 629 193.
  • Chung KF, Barnes PJ Role of platelet-activating factor in asthma. Lipids 1991 26 1277 Brief review on the effect of PAF on the airways.
  • Page CP The contribution of platelet-activating factor to allergen-induced eosinophil infiltration and bronchial hyperresponsiveness. Lipids 1991 26 1280 Brief review on the relationship of PAF and eosinophils in asthma.
  • Adamus WS, Heuer HO, Meade CJ, Schilling JC Inhibitory effects of the new PAF acether antagonist WEB 2086 on pharmacologic changes induced by PAF inhalation in human beings. Clin. Pharmacol. Ther. 1990 47 456.
  • O'Connor BJ, Ridge SM, Chen-Worsdell YM, Uden S, Barnes PJ, Chung KF Complete inhibition of airway and neutrophil responses to inhaled platelet activating factor (PAF) by an oral PAF antagonist, UK-74,505. Am. Rev. Respir. Dis. 1991 143 A156.
  • Roberts NM, McCusker M, Chung KF, Barnes PJ Effect of a PAF antagonist, BN 52063, on PAF-induced bronchoconstriction in normal subjects. Br. J. Clin. Pharmac. 1988 26 65.
  • Hsieh K-H Effects of PAF antagonist, BN52021, on the PAF-, methacholine-, and allergen-induced bronchoconstriction in asthmatic children. Chest 1991 99 877.
  • Wilkens JH, Wilkens H, Uffmann J, Bövers J, Fabel H, Frölich JC Effects of a PAF-antagonist (BN 52063) on bronchoconstriction and platelet activation during exercise induced asthma. Br. J. Clin. Pharmac. 1990 29 85.
  • Freitag A, Watson RM, Matsog G, Eastwood C, O'Bryne PM The effect of treatment with an oral platelet activating factor antagonist (WEB 2086) on allergen induced asthmatic responses in human subjects. Am. Rev. Respir. Dis. 1991 143 A157.
  • Wilkens H, Wilkens JH, Bosse S, Kempe F, Fritz S, Frölich JC, Fabel H Effects of an inhaled PAF-antagonist (WEB 2086 BS) on allergen-induced early and late asthmatic responses and increased bronchial responsiveness to methacholine. Am. Rev. Respir. Dis. 1991 143 A812.
  • Bel EH, De Smet M, Rossing TH, Timmers MC, Dijkman JH, Sterk PJ The effect of a specific oral PAF-antagonist, MK-287, on antigen-induced early and late asthmatic reactions in man. Am. Rev. Respir. Dis. 1991 143 A811.
  • Dermarkarian RM, Israel E, Rosenberg MA, Jansen A, Danzig MR, Fourre J, Drazen JM The effect of SCH 37370, a dual platelet activating factor (PAF) and histamine antagonist, on the bronchoconstriction induced in asthmatics by cold, dry air isocapnic hyperventilation (ISH). Am. Rev. Respir. Dis. 1991 143 A812.
  • Crespo MS, Fernandez-Gallardo S Pharmacological modulation of PAF: A therapeutic approach to endotoxin shock. J. Lipid. Mediators 1991 4 127 A review of the role of PAF in endotoxin shock.
  • Anderson BO, Bensard DD, Harken AH The role of platelet activating factor and its antagonists in shock, sepsis and multiple organ failure. Surg. Gynecol. Obstet. 1991 172 415.
  • Heuer HO, Darius H, Lohmann HF, Meyer J, Schierenberg M, Treese N Platelet-activating factor type activity in plasma from patients with septicemia and other disease. Lipids 1991 26 1381.
  • Griers G, Janzarik H, Kempe ER, Mueller-Eckhardt C Failure of the platelet-activating-factor antagonist WEB 2086 BS for treatment of chronic autoimmune thrombocytopenia. Blut 1990 61 21.
  • Meade CJ, Heuer H, Kempe R Biochemical pharmacology of platelet-activating factor (and PAF antagonists) in relation to clinical and experimental thrombocytopenia. Biochem. Pharmacol. 1991 41 657.
  • Terashita Z-I, Shibouta Y, Imura Y, Iwasaki K, Nishikawa K Endothelin-induced sudden death and the possible involvement of platelet activating factor (PAF). Life Sci. 1989 45 1911.
  • Filep JG, Sirois MG, Rousseau A, Fournier A, Sirois P Effects of endothelin-1 on the vascular permeability in the conscious rat: Interactions with platelet-activating factor. Br. J. Pharmacol. 1991 104 797.
  • Johnston JM, Miyaura S Platelet-activating factor: The alpha and omega of reproductive biology. Adv. Appl. Biotech. Ser. 1990 9 139.
  • O'Neill C, Wells X, Battye K Embryo-derived platelet activating factor: Interactions with the arachidonic cascade and the establishment and maintenance of pregnancy. Reprod. Fertil. Dev. 1990 2 423.
  • O'Neill C A physiological role for PAF in the stimulation of mammalian embryonic development. Trends Pharmacol. Sci. 1991 12 82 Brief review on the role of paf in the early stages of pregnancy.

Reference to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.